PMC:7025480 / 34925-36422 JSONTXT

{"project":"TEST0","denotations":[{"id":"32117250-226-232-3633053","span":{"begin":226,"end":228},"obj":"[\"26946977\"]"},{"id":"32117250-230-236-3633054","span":{"begin":230,"end":232},"obj":"[\"23147702\"]"},{"id":"32117250-136-142-3633055","span":{"begin":940,"end":942},"obj":"[\"29336943\"]"},{"id":"32117250-122-128-3633056","span":{"begin":1067,"end":1069},"obj":"[\"26946977\"]"},{"id":"32117250-126-132-3633057","span":{"begin":1071,"end":1073},"obj":"[\"23147702\"]"}],"text":"Chronic infection with P. aeruginosa in CF is subject to a complex adaptation to the CF lung leading to increased biofilm production and a decrease in the expression of various virulence factors, including secreted proteases (26, 53). In line with this, total protease activity of P. aeruginosa isolates derived from CF patients correlated with their potential to degrade IFNλ and, interestingly, the ability to degrade IFNλ was associated with intermittent infection status. At closer analysis, the capacity of IFNλ degradation of P. aeruginosa isolated from chronically infected patients clustered into two groups. Several reasons can be accounted for this observation. First, staging of patients into chronic or intermittent can be challenging for the clinician and is sometimes not entirely correct. Therefore, scientists search for additional biomarkers of chronicity because treatment of the patients is based on this classification (54). Moreover, CF patients could be colonized by several P. aeruginosa strains which do not always display the same phenotype (26, 53). Nevertheless, median IFN degradation activity was significantly decreased in chronic patients, therefore we conclude that chronic patients might have a lower risk of virus infection compared to intermittently infected patients. As discussed before, chronic patients have higher anti-AprA in the serum and this together with decreased protease activity might account for the lower infection rate seen in infected patients."}

{"project":"2_test","denotations":[{"id":"32117250-26946977-35176925","span":{"begin":226,"end":228},"obj":"26946977"},{"id":"32117250-23147702-35176926","span":{"begin":230,"end":232},"obj":"23147702"},{"id":"32117250-29336943-35176927","span":{"begin":940,"end":942},"obj":"29336943"},{"id":"32117250-26946977-35176928","span":{"begin":1067,"end":1069},"obj":"26946977"},{"id":"32117250-23147702-35176929","span":{"begin":1071,"end":1073},"obj":"23147702"}],"text":"Chronic infection with P. aeruginosa in CF is subject to a complex adaptation to the CF lung leading to increased biofilm production and a decrease in the expression of various virulence factors, including secreted proteases (26, 53). In line with this, total protease activity of P. aeruginosa isolates derived from CF patients correlated with their potential to degrade IFNλ and, interestingly, the ability to degrade IFNλ was associated with intermittent infection status. At closer analysis, the capacity of IFNλ degradation of P. aeruginosa isolated from chronically infected patients clustered into two groups. Several reasons can be accounted for this observation. First, staging of patients into chronic or intermittent can be challenging for the clinician and is sometimes not entirely correct. Therefore, scientists search for additional biomarkers of chronicity because treatment of the patients is based on this classification (54). Moreover, CF patients could be colonized by several P. aeruginosa strains which do not always display the same phenotype (26, 53). Nevertheless, median IFN degradation activity was significantly decreased in chronic patients, therefore we conclude that chronic patients might have a lower risk of virus infection compared to intermittently infected patients. As discussed before, chronic patients have higher anti-AprA in the serum and this together with decreased protease activity might account for the lower infection rate seen in infected patients."}

{"project":"MyTest","denotations":[{"id":"32117250-26946977-35176925","span":{"begin":226,"end":228},"obj":"26946977"},{"id":"32117250-23147702-35176926","span":{"begin":230,"end":232},"obj":"23147702"},{"id":"32117250-29336943-35176927","span":{"begin":940,"end":942},"obj":"29336943"},{"id":"32117250-26946977-35176928","span":{"begin":1067,"end":1069},"obj":"26946977"},{"id":"32117250-23147702-35176929","span":{"begin":1071,"end":1073},"obj":"23147702"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Chronic infection with P. aeruginosa in CF is subject to a complex adaptation to the CF lung leading to increased biofilm production and a decrease in the expression of various virulence factors, including secreted proteases (26, 53). In line with this, total protease activity of P. aeruginosa isolates derived from CF patients correlated with their potential to degrade IFNλ and, interestingly, the ability to degrade IFNλ was associated with intermittent infection status. At closer analysis, the capacity of IFNλ degradation of P. aeruginosa isolated from chronically infected patients clustered into two groups. Several reasons can be accounted for this observation. First, staging of patients into chronic or intermittent can be challenging for the clinician and is sometimes not entirely correct. Therefore, scientists search for additional biomarkers of chronicity because treatment of the patients is based on this classification (54). Moreover, CF patients could be colonized by several P. aeruginosa strains which do not always display the same phenotype (26, 53). Nevertheless, median IFN degradation activity was significantly decreased in chronic patients, therefore we conclude that chronic patients might have a lower risk of virus infection compared to intermittently infected patients. As discussed before, chronic patients have higher anti-AprA in the serum and this together with decreased protease activity might account for the lower infection rate seen in infected patients."}